Biologics (biopharmaceuticals) present new promising therapies for many diseases such as cancers, chronical inflammatory diseases and today's biggest challenge - COVID-19. Today, most biologics have been synthetized using modern methods of biotechnology, in particular DNA recombinant technology. Current pharmaceutical forms of protein/peptide biopharmaceuticals are intended for parenteral route of administration due to their instability and large size of molecules. In order to improve patient compliance, many companies are working on developing adequate forms of biopharmaceuticals for alternative, non-invasive routes of administration. The aim of this work is to review current aspirations and problems in formulation of biopharmaceuticals for alternative (non-parenteral) routes of administration and to review the attempts to overcome them. These alternative routes of administration could be promising in prevention and treatment of COVID-19, among other serious diseases. The emphasis is on stabilizing monoclonal antibodies into special formulations and delivery systems; their application should be safer, more comfortable and reliable. When it comes to hormones, vaccines and smaller peptides, some companies have already registered drugs intended for nasal and oral delivery.
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
3
Rajeev Ranjan
(2025)
Development of Complex Generics and Similar Biological Products: An Industrial Perspective of Reverse Engineering
AAPS PharmSciTech, 26(4)
10.1208/s12249-025-03087-7
Matthew A Cruz, Marco Blanco, Iriny Ekladious
(2025)
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics
mAbs, 17(1)
10.1080/19420862.2025.2550757
Deepanjan Datta, Viola Colaco, Sony Priyanka Bandi, Himanshu Sharma, Namdev Dhas, Prabhanjan S. Giram
(2025)
Polymers for Oral Drug Delivery Technologies
, ()
10.1016/B978-0-443-13774-7.00007-4The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
